Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)
Open Access
- 29 September 2023
- journal article
- research article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (2) , 272-283
Abstract
No abstract availableKeywords
Funding Information
- Actelion Pharmaceuticals
This publication has 24 references indexed in Scilit:
- Selexipag for the Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2015
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2015
- Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management eraAnnals of the Rheumatic Diseases, 2013
- The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United StatesChest, 2011
- Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management EraCirculation, 2010
- Pulmonary Arterial HypertensionChest, 2010
- Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equationEuropean Respiratory Journal, 2009
- Pulmonary Arterial Hypertension in FranceAmerican Journal of Respiratory and Critical Care Medicine, 2006
- A Confidence Interval for the Median Survival Time1982